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ABSTRACT
Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis. The 
aggressiveness and therapeutic recalcitrance of this malignancy has been attributed 
to multiple factors including the influence of an active desmoplastic stroma. How the 
stromal microenvironment of PDAC contributes to the fatal nature of this disease is 
not well defined. In the analysis of clinical specimens, we observed diverse expression 
of the hypoxic marker carbonic anhydrase IX and the lactate transporter MCT4 in the 
stromal compartment. These stromal features were associated with the epithelial 
to mesenchymal phenotype in PDAC tumor cells, and with shorter patient survival. 
Cultured cancer-associated fibroblasts (CAFs) derived from primary PDAC exhibited 
a high basal level of hypoxia inducible factor 1a (HIF1α) that was both required 
and sufficient to modulate the expression of MCT4. This event was associated with 
increased transcription and protein synthesis of HIF1α in CAFs relative to PDAC 
cell lines, while surprisingly the protein turnover rate was equivalent. CAFs utilized 
glucose predominantly for glycolytic intermediates, whereas glutamine was the 
preferred metabolite for the TCA cycle. Unlike PDAC cell lines, CAFs were resistant 
to glucose withdrawal but sensitive to glutamine depletion. Consistent with the lack 
of reliance on glucose, CAFs could survive the acute depletion of MCT4. In co-culture 
and xenograft studies CAFs stimulated the invasive potential and metastatic spread 
of PDAC cell lines through a mechanism dependent on HIF1α and MCT4. Together, 
these data indicate that stromal metabolic features influence PDAC tumor cells to 
promote invasiveness and metastatic potential and associate with poor outcome in 
patients with PDAC.
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) has 
a poor prognosis with a 5 year survival rate of less 
than 6%[1-3]. Even in patients with curative resection, 
disease recurrence occurs in the majority of cases. 
Systemic therapies have modest durable impact [4-6]; 
therefore, PDAC represents a therapy-recalcitrant disease 
for which new approaches to treatment are urgently 
needed. It is established that growth of tumor cells is 
supported by oncogenic signaling and altered metabolism 
[7-9]. Currently, it is largely unknown whether the 
metabolic wiring of cancer is induced exclusively by 
driver mutations or is a manifestation of selection in a 
particular tumor microenvironment. Understanding the 
metabolic features of PDAC, key mediators, and related 
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dependencies could yield important insights into the 
pathogenesis of disease and new targets for tumor therapy. 
Aberrant metabolism is considered one of the hallmarks 
of cancer. It has been demonstrated that KRAS and TP53 
mutations are key determinants of the PDAC metabolic 
state [10-13]. In this context, studies have shown that 
PDAC exhibits increased glycolysis and concomitant use 
of glucose intermediates into the hexosamine and pentose 
phosphate pathways. Other groups have suggested that 
PDAC is dependent on glutamine metabolism and that 
inhibition of macropinocytosis and related scavenging 
of amino acids suppresses pancreatic cancer growth in 
xenograft models [14-16]. A recent study indicated that 
there are specific metabolic subtypes of PDAC, and that 
metabolic state impacts on vulnerabilities to metabolic 
challenges and therapy [17].
The drivers of PDAC metabolic preference are 
likely reflective of both oncogenic signaling pathways and 
the unique desmoplastic stromal microenvironment [13, 
18-20]. It has been proposed that poor vascularization and 
hypoxia contribute to metabolic features of PDAC, while 
others have recently demonstrated that stromal diversity 
(activated vs. normal stroma) impacts on PDAC biology 
and prognosis [19, 21-24]. The desmoplastic stroma often 
accounts for more than 50% of the tumor mass, and this 
feature of disease is believed to contribute to PDAC 
pathogenesis and therapeutic resistance [22, 24-26]. Also, 
it has been shown that in some instances the stroma can 
constrain rampant tumorigenic growth [27, 28]. Since the 
stromal compartment accounts for the majority of PDAC 
volume, its significance to PDAC metabolism is crucial. 
Furthermore, it is recognized that targeting signaling 
pathways activated in the stroma might be necessary 
to increase the efficacy of PDAC therapy [22, 26, 29]. 
Surprisingly, relatively few analyses have delineated 
metabolic features of PDAC stroma and its impact on 
tumor cell biology. 
The hypoxic environment of PDAC and other 
tumor types is believed to contribute to the preference for 
glycolysis, with many cancer cells converting the majority 
of glucose into lactate. This metabolic preference is 
maintained even in the presence of sufficient oxygen [30, 
31]. Glycolysis, although generating a low yield of ATP 
per glucose molecule consumed, is the pathway of choice 
for rapid cell division because it generates intermediates 
for anabolic reactions [16], and is less prone to generating 
reactive oxygen species (ROS). To adapt to increased 
production of lactate, cancer cells utilize various regulation 
systems including carbonic anhydrase IX (CAIX) and 
proton-coupled monocarboxylate transporters (MCTs) 
[32-34]. CAIX buffers the extracellular environment by 
converting bicarbonate and carbon dioxide. In contrast, 
MCT proteins  modulate the extracellular pH through 
proton-coupled metabolite transport. MCT4 has generally 
been ascribed to exclusively mediate lactate efflux and 
lower extracellular pH. Both CAIX and MCT4 are targets 
of the HIF1α transcription factor and their expression 
has been postulated to denote hypoxic tumors [35, 36]. 
MCT4 is highly expressed in PDAC, associates with poor 
prognosis and glycolytic metabolism, and is required for 
glycolytic flux in cell line models [18]. In tumor cells 
with high levels of MCT4, there is an “addiction” to the 
transporter, wherein depletion leads to multiple metabolic 
adaptations, but tumor cell death occurs rapidly and 
MCT4 depletion limits tumorigenic growth in xenograft 
models [18]. Here we used a combination of primary 
PDAC tissue specimens, patient-derived cancer associated 
fibroblasts (CAFs), and extensive metabolomics analyses 
to delineate the metabolic features of PDAC stroma and 
symbiotic effects on the tumor compartment mediated by 
HIF1α and MCT4. 
RESULTS
Hypoxia markers in the tumor microenvironment 
are potent determinants of PDAC prognosis
One of the unique features of PDAC is the presence 
of abundant desmoplastic stroma, which has been 
implicated in inducing a hypoxic state by constraining 
tumor vasculature. To determine the relationship between 
hypoxia and the tumor stroma, we utilized a patient 
cohort of 203 PDAC cases (demographics, Supplemental 
Table 1). We found that the marker of hypoxia carbonic 
anhydrase IX (CAIX) was expressed in the stromal 
environment of PDAC (Figure 1A), and interestingly was 
not significantly associated with expression in the tumor 
cells (p = 0.085, Supplemental Table 2). CAIX expression 
in the stromal compartment was associated with poor 
prognosis, while the expression in the tumor cells only 
trended toward poor outcome (Figure 1B). Surprisingly, 
stromal expression of CAIX was independent of high 
stromal volume and low microvessel density (Figure 1C, 
Supplemental Table 3), but was associated with stromal 
expression of another hypoxia marker MCT4 (Figure 1D, 
Supplemental Table 3). Tumors with high levels of CAIX 
and MCT4 in the stroma had particularly poor prognosis 
(Figure 1D). To determine potential features of the tumor 
that would be related to having high levels of CAIX/MCT4 
in the stromal compartment, multiple additional markers 
were analyzed. PDAC with high stromal CAIX/MCT4 
expression were characterized by presence of high levels 
of p53 protein, which is indicative of TP53 mutations. 
Additionally, many such tumors exhibited evidence of the 
epithelial to mesenchymal transition (EMT) phenotype 
as determined by the expression of vimentin in the tumor 
cells (Figure 2A and 2B, Supplemental Table 3). Pearson 
correlation revealed that TP53 mutations and EMT were 
highly correlated with MCT4 and CAIX expression in the 
tumor stromal environment (Figure 2C). Random forest 
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Figure 1: CAIX expression in PDAC and association with outcome. A. Representative images of immunohistochemical staining 
showing: negative expression of CAIX in both tumor cell and stromal compartments (top left), positive expression of CAIX in tumor cells 
but not stromal compartment (top right), positive expression of CAIX in stromal compartment but not tumor cells (bottom left), positive 
expression of CAIX in both tumor cell and stromal compartments (bottom right). B. Kaplan-Meier analysis of CAIX expression in the 
distinct tumor cell and stromal compartments and the associated overall survival. C. Representative images of immunohistochemical 
staining showing low stromal volume and high stromal volume and low and high microvessel density D. Representative images of 
immunohistochemical staining showing: positive expression of MCT4 in tumor cell compartment and positive expression of MCT4 in 
tumor stromal compartment. Kaplan-Meier analysis of combinatorial MCT4 and CAIX expression in the stromal compartment and the 
associated overall survival. Hazard ratios and p-values for each comparison are summarized in the table.
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Figure 2: Subtypes of PDAC stroma are associated with distinct tumor features to delineate prognosis. A. Representative 
images of immunohistochemical staining showing: negative expression of TP53 in tumor cell compartment (left), positive expression 
of TP53 in tumor cell compartment (right). Kaplan-Meier analysis of combinatorial TP53 and stromal CAIX expression and the 
associated overall survival. Hazard ratios and p-values for each comparison are summarized in the table. B. Representative images of 
immunohistochemical staining showing: negative expression of vimentin in tumor cell compartment (left), positive expression of vimentin 
in tumor cell compartment (right). Kaplan-Meier analysis of combinatorial vimentin and stromal CAIX expression and the associated 
overall survival. Hazard ratios and p-values for each comparison are summarized in the table. C. Correlation heatmap for the indicated 
markers stained in the PDAC cohort. Heatmap demonstrating the expression of all markers investigated and resulting random forest 
clusters. D. Kaplan-Meier analysis of individual random forest clusters and their association with survival (left), and Kaplan-Meier analysis 
of cluster 2 compared to cluster 1 and 3 and their association with survival (center). Multivariate analysis of tumor grade, nodal status and 
random forest cluster (right). Hazard ratios and p-values for each comparison are summarized in the table (bottom). 
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Figure 3: Aberrant HIF1α expression in PDAC cancer associated fibroblasts. A. The level of MCT4 was determined in the 
indicated established pancreatic cancer cell lines and CAF cultures by immunoblotting. B. The level of MCT1 was determined in the 
indicated established pancreatic cancer cell lines and CAF cultures by immunoblotting. C. HIFα and MCT4 levels were determined by 
immunoblotting following the knockdown of HIF1α with RNAi or the induction of hypoxia through the use of CoCl2. D. The stability 
of HIF1α was evaluated in CAFs following treatment with cycloheximide. E. HIF1α was detected by immunoblotting in the presence of 
cycloheximide in the absence or presence of the proteasome inhibitor MG132. F. HIF1α protein levels were determined in the absence and 
presence of DMOG. G. RNA levels of the indicated genes as determined by microarray analyses (**p < 0.01 for tumor cell line vs. CAF). 
H. MG132 was used to interrogate the synthetic rate of HIF1α protein in the indicated cell lines. I. The expression of HIF1α target genes 
was evaluated in the indicated cell lines by microarray analysis (**p < 0.01 for tumor cell vs. CAF).
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clustering of the markers partitioned PDAC cases into 
discrete clusters (Figure 2D). In this context, cluster 2 
characterized by stromal expression of MCT4 and CAIX, 
was associated with particularly poor prognosis and 
that finding remained significant in multivariateanalysis 
(Figure 2E). In contrast, cluster 1 encompassing poorly 
vascularized tumors with the absence of CAIX and 
MCT4 in the stroma, had a better prognosis. These data 
suggest that stromal features of disease are associated with 
survival in PDAC.
CAFs exhibit elevated HIF1α and MCT4
In order to differentiate the compartment selective 
roles of hypoxia markers, we employed CAFs cultures that 
were isolated from multiple PDAC specimens. Analysis 
of CAFs cultures revealed diversity in the expression of 
MCT4, with a majority of the cultures expressing high 
levels of MCT4 protein and RNA relative to PDAC tumor 
cell lines (Figure 3A, Figure S1). CAFs did not express 
Figure 4: Unique metabolic features of cancer associated fibroblast cultures. A./B. The media from CAF cultures and PDAC 
cell lines were analyzed for glucose and glutamine consumption and the production of glutamate and lactate (*p < 0.05 or **p < 0.01 
for tumor cell line vs. CAF). C. Cells were labeled with U13C-Glucose or U13C-Glutamine and the fractional mass-labeling of carbons in 
pyruvate and lactate are shown. D. Cells were labeled with U13C-Glucose or U13C-Glutamine and the fractional mass-labeling of carbons 
in malate and citrate are shown. E. The indicated genes associated with glutamine metabolism were evaluated in the indicated cell lines 
by microarray analysis (**p < 0.01 for tumor cell line vs. CAF). F. The indicated proteins associated with glutamine metabolism were 
evaluated in the indicated cell lines by immunoblot analysis. 
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MCT1 (Figure 3B) and this finding was consistent with 
the lack of stromal MCT1 staining in PDAC clinical 
cases [18]. Interestingly, CAFs expressing high levels of 
MCT4 also harbored exceedingly high levels of HIF1α 
(Figure 3C). Knockdown studies showed that HIF1α was 
required for the expression of MCT4, and even the high 
basal levels of HIF1α could be further stimulated with 
CoCl2 and, in turn, lead to further induction of MCT4 
(Figure 3C). Protein stability is typically the most relevant 
determinant of HIF1α accumulation; however, HIF1α half-
life was approximately 5 minutes in CAFs (Figure 3D). 
Furthermore, treatment with either proteasome inhibitors 
or inhibitors of prolyl hydroxylation comparably stabilized 
HIF1α (Figure 3E and 3F). These data suggest that the 
basis for the increased HIF1α protein levels in pancreatic 
cancer CAFs is not necessarily a reflection of deficits in 
protein turnover. Rather, CAFs exhibited significantly 
elevated levels of the HIF1α transcript (Figure 3G). 
Correspondingly, with short exposure to proteasome 
inhibitor MG132 the increase in HIF1α occurred rapidly in 
CAFs relative to tumor cell lines (Figure 3H). Consistent 
with these findings, CAFs were characterized by having 
elevated basal expression of multiple HIF1α target genes 
(Figure 3I). Together, these data demonstrate that high-
levels of HIF1α/MCT4 in CAFs represent a programmed 
event.
CAFs employ glutamine as a key energy source
Since CAFs express very high levels of HIF1α, it 
would suggest that they utilize predominantly glycolytic 
metabolism. Analysis of metabolic features of the cells 
by surveying consumption and excretion of metabolites 
showed that CAFs were active for the uptake of glucose 
and glutamine relative to the glycolytic cancer cell lines 
PL45 and MiaPaCa2 (Figure 4A and 4B). Correspondingly, 
they secreted increased levels of both glutamate and 
lactate. In order to delineate the predominant utilization 
of glucose and glutamine, CAFs were labeled with U13C-
glucose and U13C-glutamine. The data indicated that, as 
expected, glucose was the predominant carbon source 
for glycolysis (Figure 4C). In contrast, glutamine was 
efficiently metabolized to TCA intermediates (Figure 4D). 
The synthesis of 13C4-succinate, -fumarate, and -malate 
(m+4) was consistent with the oxidation of glutamine 
derived 13C5-α ketoglutarate via the forward reactions of 
the TCA cycle. We also observed evidence of reductive 
carboxylation to form 13C-citrate from the glutamine 
tracer. However, the relative distributions of the m+5 
versus m+3, m+4, and m+6 mass isotopomers, which are 
characteristic of the forward reactions in the TCA plus 
pyruvate carboxylase activity, indicated that reductive 
carboxylation was not the major pathway. Analysis of 
key determinants of glutamine metabolism indicated that 
CAFs expressed high levels of glutaminase (GLS1) and 
glutamate dehydrogenase (GLUD1) that mobilized the 
metabolism of glutamine in the TCA cycle (Figure 4E 
and 4F). In contrasts to PDAC cells, CAFs expressed low 
levels of cytosolic aspartate transaminase (GOT1) and 
alanine transaminase (ALT/GPT2) indicating that each cell 
type has unique metabolic adaptations. 
In order to assess the functional significance of 
metabolite utilization, CAFs and tumor cell lines were 
depleted for glucose or glutamine (Figure 5A and S2). 
These data showed that tumor cells (e.g. PL45) were 
very sensitive to depletion of either metabolite, which 
is consistent with previously published studies [10, 18]. 
However, CAFs were selectively sensitive to glutamine 
withdrawal and resistant to the depletion of glucose 
(Figure 5A and S2). This observation was recapitulated 
in co-culture, wherein glucose withdrawal would 
selectively elicit killing of the tumor cells (Figure S2). 
Interestingly, while nutrient withdrawal resulted in cell 
death in cell lines (Figure 5B), glutamine withdrawal 
in CAFs was accompanied by cell cycle inhibition and 
induction of senescence (Figure 5C). The impact of 
glutamine withdrawal, in CAFs could be rescued with 
glutamate (Figure 5D) and α-ketoglutarate, as expected for 
utilization of glutamine within the mitochondria (Figure 
5E). Importantly, the addition of α-ketoglutarate also 
restored the proliferative capacity of the CAFs (Figure 5F). 
Consistent with the mitochondrial utilization of glutamine, 
the GLS1 and GLUD1 inhibitors BPTES (Figure 5G) and 
EGCG (Figure 5I) inhibited the growth of CAFs, whilst 
the transaminase inhibitor AOA (Figure 5H) had no effect 
on CAFs. Since, unlike tumor cells, CAFs do not appear 
to be reliant on glucose metabolism for survival, there 
was not a significant impact of MCT4 depletion on the 
viability of CAFs in spite of the exceedingly high MCT4 
levels present in the stromal cells (Figure 5J and S2).
CAFs secrete multiple metabolites that could fuel 
tumor cell proliferation
It is recognized that CAFs contribute to the biology 
of PDAC through multifactorial mechanisms. Here, 
we focused on determining which metabolites could 
be produced by CAFs and then secreted into the local 
environment to impact tumor cells. For these studies, 
two different CAF cultures with high MCT4 and HIF1α 
expression were labeled with U13C-glucose and U13C-
glutamine, and media was analyzed for the presence of 
labeled intermediates that by definition had to be derived 
from the CAFs (Figure 6A). These analyses showed 
that veritably all lactate and pyruvate recovered from 
the media arose from glucose metabolism in the CAFs 
(Figure 6B and 6C). Interestingly, of over 20 additional 
metabolites analyzed, only alanine in the media could be 
traced to glucose metabolism in the CAFs (Figure 6D). 
Glutamine metabolism was responsible for the majority 
of the extracellular pool of glutamate (Figure 6E) and 
α-ketoglutarate (Figure 6F). Glutamine-derived aspartate 
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Figure 5: Unique metabolic dependences of cancer associated fibroblasts. A. The dependence of CAFs and tumor cell lines on 
glucose or glutamine was evaluated by nutrient withdrawal from the media (***p < 0.001). B. The identification of apoptosis in tumor cell 
lines was determined through the use of cleaved caspase 3. C. The impact of glutamine and glucose withdrawal in CAFs was determined 
by BrdU incorporation, crystal violet staining, and staining for senescence-associated ß-galactosidase activity (***p < 0.001). D. The 
influence of the indicated metabolites on CAF viability was determined (Glc-glucose, Gln-glutamine, Glu-glutamate). E./F. The influence 
of the indicated metabolites on CAF viability or BrdU incorporation was determined (Glc-glucose, Gln-glutamine, aKG- α-ketoglutarate, 
NEAA-non essential amino acids) (***p < 0.001 relative to the control). G. The influence of the GLS inhibitor BPTES on cell viability of 
CAFs (***p < 0.001 relative to the control). H. The influence of aminotransferase inhibitor aminooxyacetate (AOA) on cell viability of 
CAFs. I. The influence of GLUD1 inhibitor EGCG on CAFs viability. J. The impact of MCT4 knockdown on cell viability was evaluated 
in CAFs showing minimal impact on cell viability (***p < 0.001 relative to the control). 
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and malate were also detected in media; however, this 
represented a more modest fraction of the extracellular 
pool of these metabolites (Figure 6G and 6H). Together, 
these data indicated that a surprising diversity of 
metabolites were shed by CAFs and in principle could 
impact the biology of the surrounding tumor.
Figure 6: Metabolite secretion from CAFs. A. In order to determine the specific generation of metabolites from CAFs to the 
tumor environment, cells were labeled with U13C-Glucose or U13C-Glutamine and the metabolites in the media were evaluated by mass-
spectrometry as shown in the schematic. B./H. The fractional mass-labeling of metabolites in the media as determined from cells labeled 
with U13C-Glucose (black bars) or U13C-Glutamine (blue bars).
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MCT4 is associated with extracellular 3-carbon 
metabolite pools and drives the invasive features 
of PDAC tumors
MCT4 knockdown was used to determine the effect 
on extracellular metabolite pools derived from CAF 
metabolism. These data revealed that MCT4 depletion 
limited the production of extracellular labeled lactate and 
pyruvate from CAFs (Figure 7A). In contrast, there was 
no effect on extracellular glucose-derived alanine or on 
glutamine-derived metabolites (Figure 7B). Consistent 
with these findings, there was a suppression of media 
acidification as measured by ECAR analysis (Figure 
7C). To determine if secreted metabolites impact tumor 
cells, Boyden chamber assays were employed (Figure 
7D). In this context, MCT4 high CAFs stimulated the 
invasion of PDAC cells. Knockdown of MCT4 limited 
the invasive potential, as did the knockdown of HIF1α 
(Figure 7D). Similar results were also observed using 
CAFs that exhibit intrinsically different levels of HIF1α/
MCT4 (Figure S3). In co-culture wound healing assays, 
CAFs supported invasion of the tumor cells in a manner 
similarly dependent on the presence of MCT4 (Figure 
S3). To determine whether these events were relevant in 
the context of tumorigenic capacity in vivo, subcutaneous 
xenograft models were employed, where Capan2 cells 
were injected alone or with CAFs that expressed high 
levels of MCT4. These CAFs significantly stimulated 
tumor growth (Figure 7E and 7F) and lead to formation of 
tumors that were locally invasive into the skeletal muscle 
(Figure S4). To better delineate the specific role of MCT4, 
shRNA mediated knockdown was employed in CAFs 
and they were orthotopically co-injected with Capan2 
cells in the pancreas of NSG mice (Figure 7G). In this 
context, the presence of MCT4 expressing CAFs resulted 
in larger tumor size and presence of visceral metastasis 
to the spleen and liver (Figure 7H). Metastases were not 
observed in the absence of CAFs, and were diminished 
with MCT4 knockdown in the CAFs (Figure S4). Together 
these data indicate a critical role for stromal MCT4 in 
supporting the aggressiveness of PDAC tumors.
DISCUSSION
The presence of abundant desmoplastic stroma 
represents one of the hallmarks of pancreatic cancer. It 
is believed that stroma exerts multiple effects on the 
tumor that contribute to the poor prognosis of pancreatic 
cancer [22]. In particular the analysis of cultured CAFs 
suggests that stromal cells provide secreted factors that 
can support tumor growth, invasion, and metastasis [25, 
37, 38]. The data herein suggest that the nature of the 
stromal environment is complex and has disparate effects 
on tumor biology. Notably, not all stroma exhibits elevated 
levels of CAIX and MCT4, and only this form of stroma is 
associated with particularly poor prognosis. These findings 
agree well with an emerging literature that PDAC stroma 
delineates different subtypes of disease [19], and suggest 
that the metabolic features of the surrounding stroma 
could be a key determinant of tumor aggressiveness.
While tumor metabolism has been extensively 
studied, the metabolic features of the tumor 
microenvironment are less known. In the context of 
PDAC, where neoplastic cells can represent as little 
as 10% of tumor volume, microenvironment would 
be anticipated to have a significant impact on tumor 
metabolism. It has been shown that glycolytic subtypes of 
PDAC express high-levels of MCT4 and are dependent on 
this transporter for maintenance of glycolysis and survival 
[18]. Surprisingly stromal cells can express exceedingly 
high levels of MCT4, but remain independent of MCT4 
for viability. This finding is consistent with the equally 
surprising observation that stromal cells do not require 
glucose for viability, but are dependent on glutamine. 
Glutamine is the principle fuel for CAF’s TCA through a 
GLUD1 mediated utilization of glutamine. This metabolic 
adaptation is distinct from the GOT1 mediated pathway 
that is required to support growth of PDAC cells [14]. 
Consistent with these findings, inhibitors of GLS1 and 
GLUD1 restricted the growth of stromal cells. These data 
suggest that targeting glutamine-dependent metabolic 
processes may have significant impact on desmoplastic 
stroma.
There are multiple mechanisms through which 
a stromal compartment with high-levels of MCT4 and 
CAIX could impact on tumor biology. Presumably, these 
markers could simply reflect a hypoxic tumor environment 
[39, 40]. However, our data with isolated CAFs suggest 
that the expression of MCT4 while driven by HIF1α, is 
in fact an epigenetic state that is not simply reflective of 
hypoxia. Notably HIF1α levels remain exceedingly high 
in cultures with ample oxygen. Additionally, the elevated 
HIF1α in CAFs was not reflective of disruption of oxygen 
sensing and protein stabilization as observed with loss of 
VHL [41]. Therefore, the basis of high-levels of HIF1α in 
CAFs remains under study. Importantly, not all cultured 
PDAC CAFs exhibited high HIF1α and MCT4 levels 
nor does all tumor stroma exhibit high levels of CAIX 
and MCT4; therefore indicating the presence of stromal 
diversity. 
High levels of HIF1α enhance glycolytic metabolism 
and lead to the generation of excess lactate [42]. In this 
context, acidic pH is known to contribute to tumor cell 
invasiveness and could be an important contributing factor 
for the poor prognosis observed in MCT4-high PDAC 
cases [43]. However, another possibility is that CAFs 
metabolism provides metabolic intermediates that can 
be employed by the tumor. Using metabolite tracing we 
could identify metabolites that were selectively generated 
from glucose or glutamine metabolism within the CAFs 
and secreted into media. Whether these metabolites fuel 
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Figure 7: Metabolic features of CAFs support tumor cell invasion/metastasis. A. The effect of MCT4 depletion was evaluated 
on the secretion of glucose-derived metabolites. Only the levels of lactate and pyruvate in the media were reduced with MCT4 knockdown. 
B. The effect of MCT4 depletion was evaluated on the secretion of glutamine-derived metabolites. There was no significant effect on any 
metabolite (glutamate and malate are shown). C. MCT4 knockdown limits glycolytic activity as measured by ECAR and acidification of the 
media. D. The invasive potential of Capan2 tumor cells was evaluated in modified Boyden chamber assays. CAFs were plated at the bottom 
of the wells and invasion was quantified. Data showed that CAFs supported invasion, which was dependent on the expression of HIF1α and 
MCT4 in the CAF. E. Co-injection of CAFs with Capan2 was evaluated in subcutaneous xenograft models. Impact on tumor volume and 
tumor mass was determined. F. Orthotopic co-injection was performed with CAFs and Capan2. Tumor mass and weight was significantly 
increased with MCT4 expression. G. Representative spleen metastasis observed with CAFs expressing MCT4.
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tumorigenesis and progression in the patient is unclear. 
Additionally, CAFs secrete proteins that could be 
employed by the tumor cells by macro-pinocytosis [15]. 
MCT4 knockdown in CAFs selectively impinged on the 
extracellular production of 3-carbon metabolites and 
acidification (i.e. ECAR). Since it has been hypothesized 
that acidic pH promotes local invasive growth and 
metastasis, this could represent a mechanism via which 
MCT4-high CAFs contributed to metastatic spread in 
examined models and particularly poor prognosis in 
clinical PDAC cases. 
Several studies have suggested that targeting PDAC 
microenvironment could represent an important target for 
therapeutic interventions. Based on the premise that dense 
fibrotic and vasculature-poor stroma may provide a barrier 
to effective drug delivery, strategies targeting the PDAC-
associated fibroblasts using hedgehog pathway inhibitors 
were proposed [24]. However, hedgehog inhibitors failed 
in preliminary clinical studies, and subsequent studies 
in mouse models showed that sonic hedgehog genetic 
deletion or chronic treatment with hedgehog inhibitors 
resulted in formation of poorly differentiated tumors 
and reduced survival [27, 28]. These data suggested that 
stroma, at least in some instances, can play a restrictive 
role in tumorigenesis. The data herein suggest that by 
selectively abrogating metabolic features of stroma, it 
may be possible to specifically limit tumor growth and 
aggressiveness while maintaining the restrictive role of the 
stroma on tumor biology. Consistent with this supposition 
tumors devoid of MCT4 and CAIX in the stroma have a 
better prognosis in the investigated cohort. 
Together the studies here delineate core features 
of PDAC stroma and patient-derived CAFs that provide 
insights into features of disease and potential metabolic 
vulnerabilities.
MATERIALS AND METHODS
Cell culture
The established cell lines were cultured as we have 
previously described [18]. CAFs cultures were established 
by serially trypsinizing pancreatic tumor specimens and 
isolating single cells from the tissue. Fibroblastic cultures 
were confirmed by the presence of vimentin and lack 
of cytokerain staining. CAFs were cultured in DMEM 
supplemented with 10% fetal bovine serum with antibiotic 
and antimycotic. 
Reagents
Cycloheximide (Sigma, 01810-G), MG132 (Selleck, 
50-833-9), DMOG (Frontier Scientific, D1070), BPTES 
(Sigma, SML0601), EGCG (Sigma, 03970590-10MG), 
AOA (Sigma, C13408-1G), L-Glutamic acid (Sigma, 
RES5063G-A701X), AZD6244 (Selleck Chem, S1008) 
were obtained from standard vendors. Universally labeled 
L-Glutamine (U-13C5) (Cambridge Isotope Laboratories, 
CLM-1822-H-0.1) and D-Glucose (U-13C6) (Cambridge 
Isotope Laboratories, CLM1396-1) were obtained 
from Cambridge Isotope Laboratories. Cell Titer-Glo 
Luminescent Cell viability assay (Catalog No. G7572) 
was purchased from Promega Corporation (Madison, WI).
Antibodies
The following antibodies were obtained from the 
indicated vendors: MCT4 (Santa Cruz, SC-50329, anti 
rabbit), MCT1 (Santa Cruz, SC-365501, anti mouse), 
HIF1α (Novus Biological, NB100-654, anti rabbit), CAIX 
(Novus Biological, NB100-417, anti rabbit), CD147(R&D 
system, MAB-972, anti mouse), GAPDH (Santa Cruz, 
SC25778, anti rabbit), GLUD1 (Novus Biological, 
NB600-853, anti rabbit), GOT1 (Novus Biological, NBP1-
54778, anti rabbit), ALT (Abnova, H00002875-M02A, anti 
mouse), VDAC (Abcam, ab34726, anti rabbit), β-tubulin 
(Santa Cruz, SC-9104, anti rabbit), Tom20 (Santa Cruz, 
SC-17764, anti mouse). 
Study population and tissue microarray 
construction
Specimens were obtained from 203 largely 
consecutive patients that underwent resection for 
pancreatic ductal adenocarcinoma, as was approved by 
the Institutional Review Board. Clinical and treatment 
information was extracted by chart review. Supplemental 
Table 1 contains descriptive statistics (age, tumor 
size, histologic grade, lymph-node status, stage, vital 
status, and treatment information). The tumor tissue-
microarrays (TMAs) were constructed using a tissue 
arrayer (Veridiam). TMA sections of 4 μm were used for 
immunohistochemistry. 
Immunohistochemical staining
CAIX expression levels were assessed using mouse 
monoclonal anti-CAIX antibody (clone MRQ-54, Cell 
Marque, Rocklin, CA) at a dilution of 1:500. Vimentin and 
TP53 expression levels were detected using pre-diluted, 
anti-vimentin mouse monoclonal and anti-TP53 mouse 
monoclonal antibodies, respectively (clones V9, DO-
7, Ventana, Tucson, AZ). MCT4 expression levels were 
assessed using rabbit, polyclonal anti-MCT4 antibody 
diluted at 1:250 (clone H-90, Santa Cruz Biotechnology, 
Santa Cruz, CA). CD34 expression was detected using 
pre-diluted mouse, monoclonal anti-CD34 antibody (clone 
QBEnd/10, Ventana, Tucson, AZ). Immunohistochemical 
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stains were performed using the Dako automated stainer. 
To evaluate CAIX, vimentin and TP53 expression in 
tumor epithelial cells, a quantitative scoring system was 
used based on percentage of positively staining cells. 
Specimens with 0-5% tumor epithelial cells staining for 
CAIX were considered negative and those with 6-100% 
CAIX staining were considered positive, in keeping with 
previously published criteria [44]. Specimens with any 
tumor cells staining for Vimentin (>0%) were considered 
positive. TP53 expression in the specimens was denoted 
as positive if there was >50% of tumor epithelial cell 
staining, and negative if staining equaled to or was present 
in less than 50% of tumor cells [45]. MCT4 expression in 
tumor epithelial cells was scored semi-quantitatively as 
follows: 0, 0% immuno-reactive cells; 1, < 5% immuno-
reactive cells; 2, 5-50% immune-reactive cells; and 3, 
>50% immuno-reactive cells. Similarly, intensity of 
staining was evaluated semi-quantitatively on a scale 0-3, 
with 0 representing negative, 1, weak; 2, moderate and 
3, strong staining. A final score was then calculated by 
multiplying the two individual values in order to reflect 
both the percent of immuno-reactive cells and staining 
intensity, as previously described. For survival analyses, 
epithelial MCT4 expression was categorized as positive 
for specimens with a score of 6-9, and categorized as 
negative for specimens with a score of 0-5. 
Stromal markers scoring
Stromal CAIX was scored categorically as negative 
(0, no staining) or positive (weak or strong staining). 
Stromal MCT4 staining was scored semi-quantitatively 
as negative (0, no staining), weak (1, either diffuse 
weak staining or strong staining in less than 30% of 
stromal cells) or strong (2, defined as strong staining 
of 30% or more of the stromal cells) [46]. For survival 
analyses, stromal MCT4 expression was dichotomized for 
specimens with strong staining as positive, and negative 
for specimens with none or weak staining. 
Microvessel density and stromal volume scoring
Digital pathologic assessment of blood vessels 
was performed employing microvessel density algorithm 
(Aperio, Leica Biosystems, Nussloch, GmbH). The CD34 
stained slides were scanned on an Aperio ScanScope. 
The default algorithm parameters were adjusted with the 
assistance of the Aperio MVA expert representative. The 
resulting values were stratified around the median into low 
and high groups, where low microvessel density ranged 
from 1.03 vessels/mm2 to 6.16 vessels/mm2 and high 
microvessel density from 6.2 vessels/mm2 to 38 vessels/
mm2. The percentage of stromal volume was determined 
on H&E stained whole tumor sections corresponding to 
blocks used for tissue microarray construction. Visual 
estimation of the percentage of stromal cells compared 
to tumor cells was made in one 10X magnification field. 
Stromal areas were only evaluated when surrounded 
by tumor cells in all directions. The median value for 
stromal volume (50%) was used to classify patients into 
two groups, low and high stromal volume as has been 
previously published [47].
Statistical analysis
To determine the clinical significance of biomarker 
status, we used the endpoint of overall survival. 
Biomarkers were evaluated for their association with 
survival through Kaplan-Meier analysis. Univariate and 
multivariate analysis were performed using the Cox 
regression method. Correlation between biomarkers was 
established using Spearman Rank correlation method. 
Unsupervised, random forest clustering was performed on 
the biomarkers panel. All analyses were performed using 
the survival package in R version 3.1.1; heatmaps were 
created using heatmap.2 in R.
Plasmids and RNAi
The following RNAi were employed, siMCT4 
(Santa Cruz, SC-45892), HIF1α(Sigma, NM_181054). 
The shRNA against MCT4 was introduced by lenti-viral 
transduction as previously published [18]. 
Immunoblotting
Cells were trypsinized and washed twice with 
cold PBS. Harvested samples were lysed in ice-cold 
RIPA lysis buffer (1% NP-40, 0.1% SDS, 0.25% sodium 
deoxycholate, 150 mmol/L NaCl and 50 mmol/L Tris-
HCl (pH 7.4), 1mmol/L EDTA) containing both protease 
inhibitor cocktail (Roche) and phosphatase inhibitors 
(Roche). The total protein concentration was determined 
using a Bio-Rad protein assay reagent (Bio-Rad). 
Equivalent amounts of proteins were separated by10% 
or 12% SDS-PAGE and transferred to PVDF membranes 
(Millipore, IPVH00010). After being blocked in Tris 
buffered saline (TBS) containing 5% non-fat milk, the 
membranes were incubated with primary antibodies at 
a dilution of 1:1000 at 4o C for overnight and then with 
HRP conjugated anti-mouse or anti-rabbit antibody 
(Jackson Immunoresearch) at a dilution of 1:5000 at 
room temperature for 1 hour. Signals were detected on 
X-ray film using the ECL detection reagent (GE health 
life science). Equal protein loading was assessed by the 
GAPDH or Actin.
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Transfection of RNAi
Transfection of siRNA was carried out with 
Lipofectamine RNAiMAX transfection reagent 
(Invitrogen, 13778-150) according to the procedure 
recommended by the manufacturer. Seventy-two hours 
after transfection with siRNA at various conditions, the 
cells were harvested for western blot or analyzed on a 
microplate reader (BioTek) for cell viability assay. 
Metabolomics and mass isotope labeling
For analysis of intracellular metabolites by LC/MS, 
10mM of Glucose or 4mM of Glutamine in the DMEM 
media were replaced either by U13C-Glucose or U13C-
Glutamine. 3 x 105 CAF cells were incubated with isotope 
labeled nutrient containing media for 6 and 12 hours, for 
U13C-Glucose and U13C-Glutamine labeling respectively. 
20µl of media samples in each plate were snap frozen for 
metabolite profiling of media. The preparation of lysates 
and analysis of the metabolite levels was as previously 
published [48].
Cell invasion assay
The invasive behaviors of the Capan2 cells were 
tested using a transmembrane invasion assay (0.8µm 
pore size, Costar). CAF were transfected with either 
siMCT4 RNA or siHIF1α RNA 48 hours prior. Capan2 
cells (2.0×104) were plated into the upper chamber and 
1X104 of CAF were plated in the bottom wells. Capan2 
cells were allowed to invade across the transmembrane for 
24 hours at 37 °C in 5% CO2. After incubation, cells were 
removed from the upper surface of the filter by scraping 
with a cotton swab. The invaded cells that adhered to the 
bottom of the membrane were stained with a crystal violet 
solution. The number of cells that invaded the membrane 
was determined by counting the cell number of three 
randomly selected high-power fields. 
HIF1α stability assays
3 × 105 cells were seeded on 6cm plates. After 
24 hours, later, cells were treated with 100µg/ml of 
cyclohexamide to inhibit protein synthesis. Either MG132 
(50µM) or DMOG (50µM) were employed to stabilize 
HIF1α. Samples were harvested at the indicated time 
points and lysed in RIPA buffer, then subjected to SDS 
PAGE and western blot.
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